Having trouble finding Zytiga at your pharmacy? Learn why this prostate cancer medication can be hard to locate and what steps you can take in 2026.
You've got the prescription in hand. Your doctor says you need to start Zytiga as soon as possible. But when you call your pharmacy, they tell you it's not in stock — and they're not sure when it will be. Sound familiar?
For many men being treated for advanced prostate cancer, getting access to Zytiga (Abiraterone Acetate) can feel unnecessarily difficult. The drug is FDA-approved, your doctor prescribed it, and yet finding it can turn into a frustrating scavenger hunt.
In this article, we'll break down exactly why Zytiga can be so hard to find in 2026 and what you can do about it.
Zytiga is the brand name for Abiraterone Acetate, a prescription medication used to treat certain types of advanced prostate cancer. Specifically, it's prescribed for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).
Zytiga works by blocking an enzyme called CYP17A1, which your body needs to produce testosterone. Since prostate cancer cells rely on testosterone to grow, cutting off this supply helps slow or stop the cancer's progression. It's always taken alongside a corticosteroid like prednisone and is used in combination with hormonal therapy or after surgical castration.
Zytiga comes as a tablet — either 250 mg or 500 mg — and is taken once daily on an empty stomach. A generic version of Abiraterone Acetate is also available, along with a related brand called Yonsa that uses a different tablet formulation.
There isn't just one reason Zytiga can be difficult to locate. Several factors work together to create access barriers for patients.
Unlike common medications that every pharmacy keeps on the shelf, Zytiga is classified as a specialty drug. This means it's typically dispensed through specialty pharmacies rather than your neighborhood drugstore. Many large retail pharmacies — including chains like CVS, Walgreens, and Walmart — may not routinely stock Zytiga.
Specialty pharmacies have specific agreements with manufacturers and insurers to handle high-cost, complex medications. While this system is designed to ensure proper handling and patient support, it also means fewer locations carry the drug.
Most insurance plans, including Medicare Part D, require prior authorization before they'll cover Zytiga. This means your doctor's office must submit paperwork to your insurance company proving that Zytiga is medically necessary for your condition. This process can take days or even weeks, creating delays before you can even pick up the medication.
Step therapy requirements may also apply, meaning your insurer might require you to try another treatment first before approving Zytiga.
Brand-name Zytiga can cost between $12,000 and $14,000 per month without insurance. Even generic Abiraterone Acetate ranges from $500 to $3,000 per month. Because of these high costs, many pharmacies are reluctant to keep large quantities in stock. They don't want expensive inventory sitting on the shelf, especially if they only have a few patients who need it.
Even when you find a pharmacy that carries Zytiga, insurance complications can create additional hurdles. Coverage denials, formulary restrictions, and high copays can all make it feel impossible to actually get the drug into your hands. Some patients find themselves caught between their doctor, their insurance company, and their pharmacy — each pointing to the other.
The good news is that there are practical steps you can take to improve your chances of finding Zytiga in stock.
Tools like Medfinder can help you search for pharmacies that currently have Zytiga or generic Abiraterone Acetate in stock near your location. Instead of calling pharmacy after pharmacy, you can check availability online and save yourself hours of frustration.
Your oncologist's office likely works with one or more specialty pharmacies. Ask your care team which specialty pharmacies they recommend and whether they can help coordinate your prescription. Many specialty pharmacies also offer home delivery, so you don't have to pick up the medication in person.
If cost is a barrier, several programs can help. The Janssen CarePath Savings Program may reduce your out-of-pocket cost to as little as $0 per month for commercially insured patients. The Johnson & Johnson Patient Assistance Foundation provides Zytiga at no cost to qualifying uninsured or underinsured patients. Organizations like the PAN Foundation and HealthWell Foundation also offer financial assistance.
For more details on saving money, check out our guide on how to save money on Zytiga in 2026.
Generic Abiraterone Acetate is available and is the same active ingredient as Zytiga. It's typically much less expensive and may be easier to find since more pharmacies are willing to stock it. Ask your doctor if switching to the generic version is appropriate for you.
If you know you'll need a refill, start the process early. Contact your pharmacy or specialty pharmacy at least two weeks before you run out. This gives enough time to handle any insurance issues, stock orders, or shipping delays.
Finding Zytiga shouldn't be harder than fighting the disease itself. Unfortunately, the combination of specialty pharmacy distribution, prior authorization requirements, high costs, and insurance complexity can make access a real challenge.
But you have options. Using tools like Medfinder, working closely with your oncologist's office, and exploring patient assistance programs can all help you get the medication you need without unnecessary delays.
For more practical tips, read our article on how to find Zytiga in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
